ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

Q1 2024 ACADIA Pharmaceuticals Inc Earnings Call Transcript

May 08, 2024 / 08:30PM GMT
Release Date Price: $17.13 (-0.70%)
Operator

Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 Financial Results and Operating Overview Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications. Please proceed.

Albert S. Kildani
ACADIA Pharmaceuticals Inc. - SVP of IR & Corporate Communications

Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's First Quarter 2024 Earnings.

Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss our strong commercial franchises, debut and NUPLAZID. Also joining us is Kimberly Manhard, Senior Vice President of Global Strategic Planning and Execution, who will provide an update on our pipeline programs. And Mark

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot